Supplementary analysis reveals pharmacodynamic effects of ATR kinase inhibitor elimusertib, highlighting its potential in tumors with DNA damage response alterations.
Supplementary Figure 10: Additional IHC and RPPA results from pharmacodynamic experiments.
No takes yet. Share an insight, caveat, or question.
Varadarajan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: